Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
12.81
+0.07 (0.55%)
Feb 4, 2026, 1:35 PM CST
SHE:301211 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 544.62 | 543.21 | 1,694 | 1,858 | 1,860 | 105.52 |
Trading Asset Securities | 1,026 | 1,094 | 129.4 | 103.98 | - | 240 |
Cash & Short-Term Investments | 1,570 | 1,637 | 1,824 | 1,962 | 1,860 | 345.52 |
Cash Growth | -2.92% | -10.26% | -7.05% | 5.50% | 438.28% | -4.77% |
Accounts Receivable | 56.63 | 75.53 | 75.08 | 127.47 | 161.05 | 114.21 |
Other Receivables | 5.47 | 3.8 | 2.66 | 1.35 | 3.09 | 2.11 |
Receivables | 62.1 | 79.33 | 77.74 | 128.82 | 164.14 | 116.32 |
Inventory | 122.02 | 137.85 | 173.8 | 114.7 | 89.5 | 134.59 |
Other Current Assets | 26.61 | 20.67 | 23.59 | 21.21 | 15.67 | 7.23 |
Total Current Assets | 1,781 | 1,875 | 2,099 | 2,227 | 2,129 | 603.65 |
Property, Plant & Equipment | 538.35 | 527.75 | 361.99 | 184.8 | 131.7 | 136.76 |
Long-Term Investments | 9.58 | 9.64 | - | - | - | - |
Other Intangible Assets | 67.35 | 68.94 | 71.07 | 73.27 | 66.67 | 61.45 |
Long-Term Deferred Tax Assets | 2.2 | 2.05 | 2.19 | 2.39 | 1.52 | 1.38 |
Long-Term Deferred Charges | 2.52 | 1.05 | 1.33 | - | - | - |
Other Long-Term Assets | 0.38 | 4.61 | 11.03 | 11.47 | 1.24 | - |
Total Assets | 2,401 | 2,489 | 2,547 | 2,499 | 2,330 | 803.25 |
Accounts Payable | 92.14 | 116.04 | 117.71 | 82.62 | 36.13 | 36.88 |
Accrued Expenses | 11.97 | 14.99 | 12.92 | 11.64 | 8.86 | 13.53 |
Current Portion of Leases | 1.09 | 1.59 | 1.51 | 0.97 | - | - |
Current Income Taxes Payable | 1.73 | 3.13 | 14.27 | 18.14 | 12.84 | 21.61 |
Current Unearned Revenue | 12.88 | 11.87 | 15.01 | 69.72 | 6.34 | 14.03 |
Other Current Liabilities | 7.84 | 16.76 | 13.73 | 25.82 | 38.84 | 13.04 |
Total Current Liabilities | 127.66 | 164.38 | 175.14 | 208.91 | 103.01 | 99.09 |
Long-Term Leases | 2.01 | 3.62 | 5.15 | 6.43 | - | - |
Long-Term Unearned Revenue | 2.01 | 2.04 | 2.1 | 0.22 | 0.28 | 0.34 |
Long-Term Deferred Tax Liabilities | 10.51 | 8.92 | 7.49 | 6.7 | 4.24 | 3.43 |
Total Liabilities | 142.19 | 178.97 | 189.89 | 222.26 | 107.53 | 102.85 |
Common Stock | 417.6 | 288 | 288 | 240 | 240 | 180 |
Additional Paid-In Capital | 1,627 | 1,757 | 1,757 | 1,805 | 1,805 | 463.78 |
Retained Earnings | 214.41 | 265.48 | 312.17 | 232.06 | 178.26 | 56.61 |
Comprehensive Income & Other | 0.38 | -0.3 | - | - | - | - |
Total Common Equity | 2,259 | 2,310 | 2,357 | 2,277 | 2,223 | 700.39 |
Shareholders' Equity | 2,259 | 2,310 | 2,357 | 2,277 | 2,223 | 700.39 |
Total Liabilities & Equity | 2,401 | 2,489 | 2,547 | 2,499 | 2,330 | 803.25 |
Total Debt | 3.1 | 5.22 | 6.66 | 7.4 | - | - |
Net Cash (Debt) | 1,567 | 1,632 | 1,817 | 1,955 | 1,860 | 345.52 |
Net Cash Growth | -2.79% | -10.21% | -7.04% | 5.10% | 438.28% | 0.79% |
Net Cash Per Share | 3.75 | 3.93 | 4.34 | 4.71 | 5.97 | 1.10 |
Filing Date Shares Outstanding | 417.6 | 417.6 | 417.6 | 417.6 | 417.6 | 313.2 |
Total Common Shares Outstanding | 417.6 | 417.6 | 417.6 | 417.6 | 417.6 | 313.2 |
Working Capital | 1,653 | 1,710 | 1,924 | 2,018 | 2,026 | 504.57 |
Book Value Per Share | 5.41 | 5.53 | 5.64 | 5.45 | 5.32 | 2.24 |
Tangible Book Value | 2,192 | 2,241 | 2,286 | 2,203 | 2,156 | 638.94 |
Tangible Book Value Per Share | 5.25 | 5.37 | 5.47 | 5.28 | 5.16 | 2.04 |
Buildings | - | 257.27 | 114.69 | 107.54 | 103.36 | 96.62 |
Machinery | - | 405.47 | 185.73 | 180.96 | 173.8 | 175.42 |
Construction In Progress | - | 53.5 | 228.77 | 51.56 | 2.17 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.